Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.82 0.42 (4.04%) Market Cap: 1.27 Bil Enterprise Value: 1.14 Bil PE Ratio: 0 PB Ratio: 8.08 GF Score: 36/100

Arcutis Biotherapeutics Inc DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review - Conference Call Transcript

Feb 01, 2021 / 01:30PM GMT
Release Date Price: $35.58 (+30.38%)
Operator

Good day, ladies and gentlemen and welcome to the Arcutis Conference Call.

As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Ms. Heather Armstrong, Vice President of Investor Relations and Corporate Communications. You may begin.

Heather Armstrong
Arcutis Biotherapeutics Inc - VP Investor Relations and Corporate Communications

Thank you. Good morning and welcome to our conference call and webcast to discuss our positive topline results from the DERMIS-1 and DERMIS-2 Pivotal Phase 3 studies evaluating roflumilast cream as a potential topical treatment for plaque psoriasis.

The slide views in today's webcast can be found under events and presentations and the investor section of our website at arcutis.com.

I'm joined on the call today by Frank Watanabe, President and CEO. Dr. Patrick Burnett, Chief Medical Officer; Dr. Mark Lebwohl, Professor and Dean for Clinical Therapeutics at the Icahn School of Medicane at Mount Sinai; Ken Lock, Chief Commercial Officer; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot